Analysts expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) to post sales of $20.00 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Jounce Therapeutics’ earnings. The business is scheduled to issue its next earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Jounce Therapeutics will report full year sales of $20.00 million for the current year, with estimates ranging from $80.58 million to $81.00 million. For the next year, analysts anticipate that the business will report sales of $129.86 million per share, with estimates ranging from $80.58 million to $206.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.04. The business had revenue of $20.29 million during the quarter, compared to analysts’ expectations of $19.94 million. During the same period in the prior year, the firm earned ($7.23) EPS.
A number of brokerages recently commented on JNCE. Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Friday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Jounce Therapeutics in a research note on Friday, June 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.67.
Shares of Jounce Therapeutics (NASDAQ:JNCE) traded down 1.39% during midday trading on Monday, hitting $14.92. The stock had a trading volume of 127,427 shares. The firm has a market cap of $479.74 million and a price-to-earnings ratio of 552.59. The company’s 50-day moving average price is $13.28 and its 200-day moving average price is $19.37. Jounce Therapeutics has a 12-month low of $11.05 and a 12-month high of $29.29.
COPYRIGHT VIOLATION WARNING: This news story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://stocknewstimes.com/2017/08/24/jounce-therapeutics-inc-jnce-expected-to-announce-quarterly-sales-of-20-00-million.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Paloma Partners Management Co bought a new position in shares of Jounce Therapeutics during the first quarter worth approximately $212,000. TIAA CREF Investment Management LLC bought a new position in shares of Jounce Therapeutics during the first quarter worth approximately $229,000. Teachers Advisors LLC raised its position in shares of Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after buying an additional 2,347 shares during the period. ARK Investment Management LLC raised its position in shares of Jounce Therapeutics by 558.9% in the second quarter. ARK Investment Management LLC now owns 11,932 shares of the company’s stock worth $167,000 after buying an additional 10,121 shares during the period. Finally, Nationwide Fund Advisors raised its position in shares of Jounce Therapeutics by 203.3% in the second quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock worth $168,000 after buying an additional 8,007 shares during the period. Institutional investors and hedge funds own 40.83% of the company’s stock.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.
Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
